February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session
4:
67
Case Study 1: Idarubicin in AML
Sensitivity analysis
(12, 25, 35, 45, 65, 90) Best Case
Worst Case
·
Level
.958
.866
·
P value
.008
.017
·
Estimate
.182
.171
·
95% CI
(.034,.325)
(.015,.347)